Operating signal within 12 months from two or more independent sources.
What they make
Pharmaceutical Preparation Manufacturing325412AyuVis is developing immunotherapies using small molecules to prevent and treat life-threatening diseases including bronchopulmonary dysplasia, retinopathy of prematurity, and pulmonary arterial hypertension. The company's approach involves modulating white blood cells to address inflammation and infection in ICU patients, with small molecules designed to be simple to synthesize and produce. The therapies are intended to serve patients with conditions that currently lack effective treatment options.
SUMMARIZED FROM THE COMPANY’S OWN WEBSITE
Where it is
Location not verified — this address could not be matched to Census TIGER, so the facility is not placed on the map.
Other plants nearby
No other listed facility within 40 km shares this one’s four-digit industry code, or this record has no coordinates to measure from.
Also at this address
No other federal record shares this street address.
WHERE THIS RECORD COMES FROM — 2 FEDERAL SOURCES, 7 FIELDS
Every fact on this page traces to a public federal filing. The table below names which register holds this facility, whether that register proves the plant operates or only that it exists, and when each of them last saw it.
| Source | Evidence | First seen | Last seen |
|---|---|---|---|
| COMPANY SITE | OPERATING | JUL 2026 | AUG 2026 |
| SAM GOV | OPERATING | APR 2026 | APR 2026 |
FIELD BY FIELD — WHICH SOURCE SUPPLIED WHAT
| FIELD | SOURCE | SIGNAL |
|---|---|---|
| ADDRESS LINE1 | SAM GOV | APR 2026 |
| CAGE CODE | SAM GOV | APR 2026 |
| CITY | SAM GOV | APR 2026 |
| NAME | SAM GOV | APR 2026 |
| REGISTRATION EXPIRATION | SAM GOV | APR 2026 |
| STATE | SAM GOV | APR 2026 |
| WEBSITE | SAM GOV | APR 2026 |
Status is computed from independent sources; nothing here is self-reported unless marked Claimed.